DOES FAMILIAL AMYLOIDOTIC POLYNEUROPATHY CAUSE COGNITIVE CHANGES?
Keywords:
Amyloid Neuropathies Familial, Dementia, Mental Status and Dementia Tests, Cognition, HeredityAbstract
Objective: The aim of this study was to evaluate the cognitive functions of patients with familial amyloid polyneuropathy followed up in a tertiary hospital in Fortaleza- CE. Methods: A cross-sectional study was carried out from January- November 2019. The population consisted of patients with FAP confirmed by genetic testing. The group of patients was compared to the control group. For the cognitive evaluation, the ACE-R (Revised Addenbrooke Cognitive Examination), FAB (Frontal Evaluation Battery) and Brief Cognitive Battery were used. Results: The final population consisted of 8 patients. The scores of ACE-R, FAB, MMSE and scores by specific cognitive area were lower in the group of patients. There was a trend of worse performance in the group of patients in the anterograde memory. Conclusion: Our study carried out the first cognitive evaluation in the Ceará population of patients with FAP. Neuroimaging can bring more data.
Downloads
Download data is not yet available.
References
1. Harris PA, Taylor R, Payne J, Gonzalez N, Conde JG, Research electronic data capture (REDCap). A metadata driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42(2): 377- 381. DOI 10.1016/j.jbi.2008.08.010
2. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin; what do they tell us about this protein and the design of drugs for TRR amyloidosis? Curr Med Chem 2012; 19 (15): 2324-42. DOI: 10.2174/092986712800269335
3. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneu-ropathy: a randomized clinical trial. Jama 2013; 310 (24): 2658- 2667. DOI: 10.1001/jama.2013.283815
4. Coelho T, Maurer MS, Suhr OB, THAOS- The transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wildtype transthyretin amyloidosis. Curr Med Res Opin 2013; 29 (1): 63-76. DOI: 10.1185/03007995.2012.754348
5. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular patho-genesis and diseade-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86: 1036- 1043. DOI 10.1136/jnnp-2014-308724
6. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, et al. Epi-demilogy of familial amyloid polyneuropathy in Japan: Identification of a novel en-demic focus. Journal of the neurological sciences 2008 Jul 15; 270: 133-140. DOI: 10.1016/j.jns.2008.02.019
7. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloido-tic olyneuropathy (FAP)- type I in Povoa do Varzim and Vila do Conde (nrth of Por-tugal). American Journal of Medical Genetics 1995. Dec 18; 60 (6): 512- 521. DOI: 10.1002/ajmg.1320600606
8. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993 Sep- Oct; 43 (5): 288- 294. DOI: 10.1159/000154146
9. Parman Y, Adams D, Obici L, Galan L, Guergueltchera V, Suhr O, et al. 60 years of TTR-FAP in Europe- where are we now? A Europe Network approach to definig the epidemiology and management patters for transthyretin familia amyloid polyneurop-athy Current opinion in neurology submitted. DOI:10.1097/WCO.0000000000000288.
10. Zhen DB, Swiecicki PL, Zeldenrust SR, Dispenzieri A, Mauermann ML, Gertz MA. Frequencies and geographic distribution of genetic mutations in transthyretin- and non- transthyretin- related familial amyloidosis. Clin Genet 2015 Oct; 88 (4): 396- 400. DOI: 10.1111/cge.12500
11. Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropa-thy (FAP) presentation in Brazil. Amyloid 2012; 19: 65-67. DOI: 10.3109/13506129.2012.673183
12. Lavigne- Moreira C, Marques VD, Gonçalves MVM, Oliveira FO, Tomaselli PJ, Nunez JC. Nascimento OJM, Barreira AA, Marques W. The genetic heterogeneity oh hereditary transthyretin amyloidosis in a sample of the Brazilian population. Journal of the Peripheral Nervous System 2018; (23): 134-137. DOI: 10.1111/jns.12259
13. Misu K et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met 30- associated familial amyloid polyneuropathy) unrelated to endemic focus in Ja-pan. Brain; 1999 (122): 1951-1962. DOI: 10.1093/brain/122.10.1951
14. Maia LF, Magalhães R, Freitas J, et al. CNS involvemente in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neuro-surg Psychiatry, 2015; 86: 159-167. DOI: 10.1136/jnnp-2014-308107
15. Martins da Silva A, Cavaco S, Fernandes J, Samões R, Alves C, Mardoso M, Kelly JW, Monteiro C, Coelho T. Age-dependent cognitive dysfunction in untreated here-ditary transthyretin amyloidosis. Journal of Neurology, 2018 Feb; 265 (2): 299-3017. DOI: 10.1007/s00415-017-8668-8.
16. Freitas Castro V, Alves PN, Franco AC, Martins IP, Conceição I. Cognitive impair-ment in liver transplanted patients with transthyretin-related hereditary amyloid pol-yneuropathy. Amyloid 2017 Jun; 24 (92): 110-114. DOI: 10.1080/13506129.2017.1335639.
2. Palaninathan SK. Nearly 200 X-ray crystal structures of transthyretin; what do they tell us about this protein and the design of drugs for TRR amyloidosis? Curr Med Chem 2012; 19 (15): 2324-42. DOI: 10.2174/092986712800269335
3. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneu-ropathy: a randomized clinical trial. Jama 2013; 310 (24): 2658- 2667. DOI: 10.1001/jama.2013.283815
4. Coelho T, Maurer MS, Suhr OB, THAOS- The transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wildtype transthyretin amyloidosis. Curr Med Res Opin 2013; 29 (1): 63-76. DOI: 10.1185/03007995.2012.754348
5. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular patho-genesis and diseade-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86: 1036- 1043. DOI 10.1136/jnnp-2014-308724
6. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, et al. Epi-demilogy of familial amyloid polyneuropathy in Japan: Identification of a novel en-demic focus. Journal of the neurological sciences 2008 Jul 15; 270: 133-140. DOI: 10.1016/j.jns.2008.02.019
7. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloido-tic olyneuropathy (FAP)- type I in Povoa do Varzim and Vila do Conde (nrth of Por-tugal). American Journal of Medical Genetics 1995. Dec 18; 60 (6): 512- 521. DOI: 10.1002/ajmg.1320600606
8. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered 1993 Sep- Oct; 43 (5): 288- 294. DOI: 10.1159/000154146
9. Parman Y, Adams D, Obici L, Galan L, Guergueltchera V, Suhr O, et al. 60 years of TTR-FAP in Europe- where are we now? A Europe Network approach to definig the epidemiology and management patters for transthyretin familia amyloid polyneurop-athy Current opinion in neurology submitted. DOI:10.1097/WCO.0000000000000288.
10. Zhen DB, Swiecicki PL, Zeldenrust SR, Dispenzieri A, Mauermann ML, Gertz MA. Frequencies and geographic distribution of genetic mutations in transthyretin- and non- transthyretin- related familial amyloidosis. Clin Genet 2015 Oct; 88 (4): 396- 400. DOI: 10.1111/cge.12500
11. Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropa-thy (FAP) presentation in Brazil. Amyloid 2012; 19: 65-67. DOI: 10.3109/13506129.2012.673183
12. Lavigne- Moreira C, Marques VD, Gonçalves MVM, Oliveira FO, Tomaselli PJ, Nunez JC. Nascimento OJM, Barreira AA, Marques W. The genetic heterogeneity oh hereditary transthyretin amyloidosis in a sample of the Brazilian population. Journal of the Peripheral Nervous System 2018; (23): 134-137. DOI: 10.1111/jns.12259
13. Misu K et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met 30- associated familial amyloid polyneuropathy) unrelated to endemic focus in Ja-pan. Brain; 1999 (122): 1951-1962. DOI: 10.1093/brain/122.10.1951
14. Maia LF, Magalhães R, Freitas J, et al. CNS involvemente in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neuro-surg Psychiatry, 2015; 86: 159-167. DOI: 10.1136/jnnp-2014-308107
15. Martins da Silva A, Cavaco S, Fernandes J, Samões R, Alves C, Mardoso M, Kelly JW, Monteiro C, Coelho T. Age-dependent cognitive dysfunction in untreated here-ditary transthyretin amyloidosis. Journal of Neurology, 2018 Feb; 265 (2): 299-3017. DOI: 10.1007/s00415-017-8668-8.
16. Freitas Castro V, Alves PN, Franco AC, Martins IP, Conceição I. Cognitive impair-ment in liver transplanted patients with transthyretin-related hereditary amyloid pol-yneuropathy. Amyloid 2017 Jun; 24 (92): 110-114. DOI: 10.1080/13506129.2017.1335639.
Downloads
Published
2021-07-27
How to Cite
1.
Mesquita Torres D, Albuquerque de Brito L, Leite Rodrigues C, Cavalcante França Júnior M, Anízio Ferreira Frota N. DOES FAMILIAL AMYLOIDOTIC POLYNEUROPATHY CAUSE COGNITIVE CHANGES?. Cadernos ESP [Internet]. 2021 Jul. 27 [cited 2024 Jul. 3];15(1):18-24. Available from: https://cadernos.esp.ce.gov.br/index.php/cadernos/article/view/522
Conference Proceedings Volume
Section
Original Article
Categories
License
Copyright (c) 2021 Cadernos ESP
This work is licensed under a Creative Commons Attribution 4.0 International License.
Received 2021-04-14
Accepted 2021-05-31
Published 2021-07-27
Accepted 2021-05-31
Published 2021-07-27
